Inderes is a hub connecting investors and listed companies. We are home to over 70 000 investors and 400 Nordic listed companies. Log in to keep up with your favourite companies!
Puuilo released a Q2 report that was quite in line with expectations. Strong revenue growth was driven by both new store openings and growth in existing stores. Profitability rose to near the historic highs of the COVID era due to favorable sales mix and successful cost control.
Inderes' August sales came in slightly below our estimate. While the muted 3% growth was driven by IR software our take is that event business saw monthly volatility being on the downside. For September we expect input 12% growth, which after August seems elevated. However, we note that the timing of CMDs and other events may give the required boost for the next month.
OptiCept has reached an agreement to bring forward the exercise period for all outstanding warrants, resulting in the subscription of 4,350,000 shares worth around 13 MSEK. We had previously flagged that this was a possibility, so the outcome is roughly in line with our expectations, even though the exercise of the warrants was in our estimates for 2025. This will therefore have a minor impact on our estimates.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Puuilo's Q2 (May-July) figures were broadly in line with our expectations in terms of profitability. The strong but slightly lower than expected revenue growth was driven by a network that grew by several stores year-on-year and by a healthy increase in sales from older stores.
Despite its early stage of development, the company is a leading global player in a rapidly growing and evolving industry. The key risk to the stock is the capital required to scale up production, which we believe will be the dividing line between successful cellular agriculture companies and others. If cellular agriculture delivers, we expect the winners of the industry to be rewarded with significant first-mover advantages and an attractive long-term investment horizon.
The August figures for the Swedish clothing market were published this morning. August sales increased by 2%. Due to minor changes, the cumulative figure for the year was no longer published, but we estimate it to be around 1%.
Neste lowered its Renewable Products guidance for the current year on Wednesday. The underlying factors are more or less the same as before, and we continue to believe that such low margins will not last in the long run. We therefore believe that the segment's performance will recover in the medium term, although there is uncertainty about the timing of the stabilization of supply and demand.
As expected, Innofactor announced yesterday that Onni Bidco Oy has received all necessary regulatory approvals for its voluntary recommended public cash tender offer for all the shares in Innofactor Plc.
We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they can apply for marketing authorization and commercialize a drug.
Puuilo will report its Q2 results on Thursday September 12 at 8:30 am EEST. Although the retail trade has seen a slowdown recently, we believe the company was one of the market winners, as in previous quarters.
OptiCept has announced that it has entered into a Memorandum of Understanding (MoU) with Saab, a key player within the defense industry. The Mou is intended to explore the possibility of forming a long-term partnership in Thailand focused on productivity improvements for the food and forestry sectors.
Tecnotree held an investor event on Friday in an attempt to provide background information on the Pericius deal. However, we did not get answers to all the worrying details. The company also issued cash flow guidance for next year and published a dividend policy, according to which free cash flow (and profit distribution) are set to remain slim and below our expectations. Given the weak cash flow and the ongoing uncertainties regarding corporate governance, we recommend that investors remain on the sidelines, at least for the time being, due to the elevated risk profile.
Revenio's subsidiary Icare yesterday announced the launch of the iCare ST500 packing the essential features of iCare rebound tonometry technology into a modern slit lamp-based design.
he start of the collaboration was announced earlier this spring, so the press release comes as no surprise, although the agreement announced now provides a concrete indication of the first steps of the collaboration. According to the release, the collaboration at this stage includes the use of Aiforia's AI solutions in the analysis of tissue samples from prostate cancer patients and the use of Aiforia's AI model development software.
Solwers: an industry consolidator in the field of technical consulting and design with 29 operational subsidiaries in Finland and Sweden. Growth strategy: more M&A’s on the agenda! Our current recommendation: Buy! Analyst Petri Gostowski summarizes.
Finnish listed IT services companies' organic revenue decline accelerated slightly, although the comparison period was already weak for several of them.
Consumer demand remains weak, which has led us to slightly lower our forecasts for this year. Our forecast for the adj. EBIT is now 108 MEUR, while Fiskars has guided for a result slightly above last year's level of 110 MEUR.
